Leukemia, Myelogenous, Chronic, BCR-ABL Positive
This graph shows the total number of publications written about "Leukemia, Myelogenous, Chronic, BCR-ABL Positive" by people in the URMC Research Network by year, and whether "Leukemia, Myelogenous, Chronic, BCR-ABL Positive" was a major or minor topic of these publication.
Below are the most recent publications written about "Leukemia, Myelogenous, Chronic, BCR-ABL Positive" by people in Profiles.
-
Liesveld JL. CML: Defining the efficacy of targeted therapy with the TARGET system. Leuk Res. 2011 May; 35(5):575-6.
-
Zhang L, Bennett JM, Zhang X, Moscinski L, Ibarz-Pinilla J, List AF, Komrokji R. Uncommon of the uncommon: low-grade myelodysplastic syndrome evolving into chronic myelogenous leukemia. J Clin Oncol. 2011 May 20; 29(15):e434-6.
-
Ito T, Kwon HY, Zimdahl B, Congdon KL, Blum J, Lento WE, Zhao C, Lagoo A, Gerrard G, Foroni L, Goldman J, Goh H, Kim SH, Kim DW, Chuah C, Oehler VG, Radich JP, Jordan CT, Reya T. Regulation of myeloid leukaemia by the cell-fate determinant Musashi. Nature. 2010 Aug 5; 466(7307):765-8.
-
Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, Hjorth-Hansen H, Höglund M, Kovanen P, Laurinolli T, Liesveld J, Paquette R, Pinilla-Ibarz J, Rauhala A, Shah N, Simonsson B, Sinisalo M, Steegmann JL, Stenke L, Porkka K. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. 2009 Aug; 23(8):1398-405.
-
Jones D, Kamel-Reid S, Bahler D, Dong H, Elenitoba-Johnson K, Press R, Quigley N, Rothberg P, Sabath D, Viswanatha D, Weck K, Zehnder J. Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology. J Mol Diagn. 2009 Jan; 11(1):4-11.
-
Lee SJ, Kukreja M, Wang T, Giralt SA, Szer J, Arora M, Woolfrey AE, Cervantes F, Champlin RE, Gale RP, Halter J, Keating A, Marks DI, McCarthy PL, Olavarria E, Stadtmauer EA, Abecasis M, Gupta V, Khoury HJ, George B, Hale GA, Liesveld JL, Rizzieri DA, Antin JH, Bolwell BJ, Carabasi MH, Copelan E, Ilhan O, Litzow MR, Schouten HC, Zander AR, Horowitz MM, Maziarz RT. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood. 2008 Oct 15; 112(8):3500-7.
-
Lichtman MA. Is there an entity of chemically induced BCR-ABL-positive chronic myelogenous leukemia? Oncologist. 2008 Jun; 13(6):645-54.
-
Young FM, Campbell A, Emo KL, Jansson J, Wang PY, Jordan CT, Mullen CA. High-risk acute lymphoblastic leukemia cells with bcr-abl and INK4A/ARF mutations retain susceptibility to alloreactive T cells. Biol Blood Marrow Transplant. 2008 Jun; 14(6):622-30.
-
Guzman ML, Li X, Corbett CA, Rossi RM, Bushnell T, Liesveld JL, Hébert J, Young F, Jordan CT. Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8). Blood. 2007 Dec 15; 110(13):4436-44.
-
Szych CM, Liesveld JL, Iqbal MA, Li L, Siebert S, Asmus C, O'Malley J, Lee A, Wang N. Isodicentric Philadelphia chromosomes in imatinib mesylate (Gleevec)-resistant patients. Cancer Genet Cytogenet. 2007 Apr 15; 174(2):132-7.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
|
